741 related articles for article (PubMed ID: 28202353)
41. Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice.
Jiang H; Tao W; Zhang M; Pan S; Kanwar JR; Sun X
Cancer Invest; 2010 Jan; 28(1):74-84. PubMed ID: 20001297
[TBL] [Abstract][Full Text] [Related]
42. The use of nanoparticulate delivery systems in metronomic chemotherapy.
Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
[TBL] [Abstract][Full Text] [Related]
43. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
44. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.
Daenen LG; Shaked Y; Man S; Xu P; Voest EE; Hoffman RM; Chaplin DJ; Kerbel RS
Mol Cancer Ther; 2009 Oct; 8(10):2872-81. PubMed ID: 19825805
[TBL] [Abstract][Full Text] [Related]
45. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Shi S; Tao L; Song H; Chen L; Huang G
APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
[TBL] [Abstract][Full Text] [Related]
46. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
47. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
Cruz-Munoz W; Man S; Kerbel RS
Clin Cancer Res; 2009 Aug; 15(15):4867-74. PubMed ID: 19622578
[TBL] [Abstract][Full Text] [Related]
48. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
49. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
Hida K; Kikuchi H; Maishi N; Hida Y
Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
[TBL] [Abstract][Full Text] [Related]
50. Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.
Jellvert Å; Åhs D; Olausson J; Franck Lissbrant I; Damber JE; Welén K
Acta Oncol; 2018 Jul; 57(7):895-901. PubMed ID: 29299975
[TBL] [Abstract][Full Text] [Related]
51. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
52. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
Norrby K
APMIS; 2014 Jul; 122(7):565-79. PubMed ID: 24164171
[TBL] [Abstract][Full Text] [Related]
53. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
Kerbel RS
Cancer Res Treat; 2007 Dec; 39(4):150-9. PubMed ID: 19746237
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.
Ciccolini J; Barbolosi D; Meille C; Lombard A; Serdjebi C; Giacometti S; Padovani L; Pasquier E; André N
Cancer Res; 2017 Sep; 77(17):4723-4733. PubMed ID: 28655786
[TBL] [Abstract][Full Text] [Related]
55. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.
Martin-Padura I; Marighetti P; Agliano A; Colombo F; Larzabal L; Redrado M; Bleau AM; Prior C; Bertolini F; Calvo A
Lab Invest; 2012 Jul; 92(7):952-66. PubMed ID: 22546866
[TBL] [Abstract][Full Text] [Related]
56. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Ng SS; Sparreboom A; Shaked Y; Lee C; Man S; Desai N; Soon-Shiong P; Figg WD; Kerbel RS
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4331-8. PubMed ID: 16857808
[TBL] [Abstract][Full Text] [Related]
57. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
[TBL] [Abstract][Full Text] [Related]
58. Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.
Mazzucchelli S; Bellini M; Fiandra L; Truffi M; Rizzuto MA; Sorrentino L; Longhi E; Nebuloni M; Prosperi D; Corsi F
Oncotarget; 2017 Jan; 8(5):8383-8396. PubMed ID: 28039473
[TBL] [Abstract][Full Text] [Related]
59. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.
Bagri A; Berry L; Gunter B; Singh M; Kasman I; Damico LA; Xiang H; Schmidt M; Fuh G; Hollister B; Rosen O; Plowman GD
Clin Cancer Res; 2010 Aug; 16(15):3887-900. PubMed ID: 20554752
[TBL] [Abstract][Full Text] [Related]
60. Metronomic low-dose chemotherapy as antiangiogenic therapeutic strategy for cancer.
Gille J; Spieth K; Kaufmann R
J Dtsch Dermatol Ges; 2005 Jan; 3(1):26-32. PubMed ID: 16353746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]